Candel Therapeutics (NASDAQ:CADL) vs. Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) Financial Review

Candel Therapeutics (NASDAQ:CADL) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares Candel Therapeutics and Quantum Genomics Société Anonyme’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	$120,000.00	1,933.43	-$37.94 million	($1.28)	-6.09
Quantum Genomics Société Anonyme	N/A	N/A	N/A	N/A	N/A

Quantum Genomics Société Anonyme has lower revenue, but higher earnings than Candel Therapeutics.

Profitability

This table compares Candel Therapeutics and Quantum Genomics Société Anonyme’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-206.10%	-82.49%
Quantum Genomics Société Anonyme	N/A	N/A	N/A

Institutional & Insider Ownership

13.9% of Candel Therapeutics shares are held by institutional investors. 44.6% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Candel Therapeutics has a beta of -0.94, meaning that its stock price is 194% less volatile than the S&P 500. Comparatively, Quantum Genomics Société Anonyme has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Candel Therapeutics and Quantum Genomics Société Anonyme, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	0	0	1	0	3.00
Quantum Genomics Société Anonyme	0	0	0	0	N/A

Candel Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 41.03%. Given Candel Therapeutics’ higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Quantum Genomics Société Anonyme.

Summary

Candel Therapeutics beats Quantum Genomics Société Anonyme on 5 of the 8 factors compared between the two stocks.

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

About Quantum Genomics Société Anonyme

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.